Skip to main content
Loading

SIRPant Immunotherapeutics, Inc.

February 26, 2024
Gene/Cell Therapy
SIRPant Immunotherapeutics, Inc.
SIRPant Immunotherapeutics, Inc., a clinical stage company, programs the cells that drive immunity – macrophages – to mobilize effective polyclonal anti-cancer immune responses, providing a novel multipronged approach to combat aggressive tumors.
Testimonials

Double Helix


 

Supporting Bank Sponsor


 

Premier Sponsors

Conference Sponsors


 

Sign up for updates

Stay up-to-date on the BIO CEO and Investor Conference via email.

SIGN UP